Co-led Adcytherix's €105M Series A — the largest ADC-focused Series A in Europe in 2025.
Adcytherix is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-drug conjugates (ADCs) to address high unmet medical needs in oncology
Adcytherix is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-drug conjugates (ADCs) to address high unmet medical needs in oncology. The company combines clinically validated targets with innovative payloads derived from approved cancer drugs to tackle cancers resistant to current therapies.